Propiverine Compared to Oxybutynin in Neurogenic Detrusor Overactivity - Results of a Randomized, Double-blind, Multicenter Clinical Study

European Urology

Volumn 51, Issue 1, 2007, Pages 235-242

  Stöhrer, Manfred ^a   Mürtz, Gerd ^b   Kramer, Guus ^c   Schnabel, Frieder ^b   Arnold, Edwin P ^d   Wyndaele, Jean Jaques ^e  

^a BG UNFALLKLINIK MURNAU   (Germany)

^b Fa Apogepha   (Germany)

^c GGZ inGeest Psychiatry   (Netherlands)

^d Department of Urology ^*  (New Zealand)

^e ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Anticholinergics; Neurogenic detrusor overactivity; Oxybutynin; Propiverine hydrochloride

Indexed keywords

OXYBUTYNIN; PROPIVERINE;

ADULT; AGE DISTRIBUTION; AGED; ANTICHOLINERGIC SYNDROME; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTOMETRY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROGENIC BLADDER; OVERACTIVE BLADDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; URODYNAMICS; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; BENZILATES; CHOLINERGIC ANTAGONISTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MANDELIC ACIDS; MIDDLE AGED; MUSCARINIC ANTAGONISTS; URINARY BLADDER; URINARY BLADDER, NEUROGENIC; URINARY BLADDER, OVERACTIVE; URODYNAMICS;

EID: 33751429185     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2006.03.016     Document Type: Article

References (21)

1. Cardozo L.D., Cooper D., and Versi E. Oxybutynin chloride in the management of idiopathic detrusor instability. Neurourol Urodyn 6 (1987) 256-257
2. Thuroff J.W., Bunke B., Ebner A., Faber P., de Geeter P., Hannappel J., et al. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. J Urol 145 (1991) 813-816
3. Gajewski J.B., and Awad S.A. Oxybutynin versus propantheline in patients with multiple sclerosis and detrusor hyperreflexia. J Urol 135 (1986) 966-968
4. Andersson K.E., Appell R., Cardozo L., Chapple C., Drutz H., Fourcroy J., et al. Pharmacological treatment of urinary incontinence. In: Abrams P., Cardozo L., Khoury S., and Wein A. (Eds). Incontinence. Edition 2005 (2005), Health Publication Ltd, Paris 809-854 Chapter 14
5. Chapple C., Khullar V., Gabriel Z., and Dooley J.A. The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur Urol 48 (2005) 5-26 Corrigendum. Eur Urol 2005;48:875
6. Bennett N., O'Leary M., Patel A.S., Xavier M., Erickson J.R., and Chancellor M.B. Can higher doses of oxybutynin improve efficacy in neurogenic bladder?. J Urol 171 (2004) 749-751
7. Madersbacher H., and Mürtz G. Efficacy, tolerability and safety profile of propiverine in the treatment of the overactive bladder (non-neurogenic and neurogenic). World J Urol 19 (2001) 324-335
8. Madersbacher H., Halaška M., Voigt R., Alloussi S., and Höfner K. A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. BJU Int 84 (1999) 646-651
9. Dorschner W., Stolzenburg J.U., Griebenow R., Halaska M., Schubert G., Mürtz G., et al. Efficacy and cardiac safety of propiverine in elderly patients - A double-blind, placebo-controlled clinical study. Eur Urol 37 (2000) 702-708
10. Jünemann K.P., Halaska M., Rittstein T., Mürtz G., Schnabel F., Brünjes R., and Nurkiewicz W. Propiverine versus tolterodine - efficacy and tolerability in patients with overactive bladder. Eur Urol 48 (2005) 478-482
11. Mazur D., Göcking K., Wehnert J., Dorschner W., Schubert G., Herfurth G., et al. Klinische und urodynamische Effekte einer oralen Propiverintherapie bei neurogener Harninkontinenz. Urologe [A] 33 (1994) 447-452
12. Stöhrer M., Madersbacher H., Richter R., Wehnert J., and Dreikorn K. Efficacy and safety of propiverine in SCI-patients suffering from detrusor hyperreflexia - a double-blind, placebo-controlled clinical trial. Spinal Cord 37 (1999) 196-200
13. Abrams P., Cardozo L., Fall M., Griffiths D., Rosier P., Ulmsten U., et al. The standardisation of terminology of lower urinary tract function: Report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodynamics 21 (2002) 167-178
14. Madersbacher H. The various types of neurogenic bladder dysfunction: an update of current therapeutic concepts. Paraplegia 28 (1990) 217-229
15. Stöhrer M., Castro-Diaz D., Chartier-Kastler E., Kramer G., Mattiasson A., and Wyndaele J.-J. EAU Guidelines on neurogenic lower urinary tract dysfunction. European Association of Urology (2003). http://www.uroweb.org/files/uploaded_files/guidelines/neurogenic.pdf
16. Ockrim J., Laniado M.E., Khoubehi B., Renzetti R., Agro E.F., Carter S.S., et al. Variability of detrusor overactivity on repeated filling cystometry in men with urge symptoms: comparison with spinal cord injury patients. BJU Int 95 (2005) 587-590
17. Madersbacher H., Stöhrer M., Richter R., Burgdörfer H., Hachen H.J., and Mürtz G. Trospium chloride versus oxybutynin: A randomized, double-blind, multicentre trial in the treatment of detrusor hyperreflexia. Br J Urol 75 (1995) 452-456
18. Stöhrer M., Bauer P., Giannetti B.M., Richter R., Burgdorfer H., and Mürtz G. Effect of trospium chloride on urodynamic parameters in patients with detrusor hyperreflexia due to spinal cord injuries. A multicentre placebo-controlled double-blind trial. Urol Int 47 (1991) 138-143
19. Schurch B., Stöhrer M., Kramer G., Schmid D.M., Gaul G., and Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs ? Preliminary results. J Urol 164 (2000) 692-697
20. Ethans K.D., Nance P.W., Bard R.J., Casey A.R., and Schryvers O.I. Efficacy and safety of tolterodine in people with neurogenic detrusor overactivity. J Spinal Cord Med 27 (2004) 214-218
21. Madersbacher H, Menarini M, Dörsam J, Sember ME, Chiang H. Anticholinergic therapy of neurogenic detrusor overactivity: Evaluation of an oral trospium chloride (TC) dose adjustment. German Society of Urology. Poster presented at the Annual Meeting 2004.